Amylin won a small victory by obtaining a restraining order from a federal judge in its suit to prevent Eli Lilly from selling BI's competitive drug, linagliptin, to the LIlly/Amylin developed Byetta with the same sales force it had dedicated to the latter.
Judge Janis Sammartino noted "love triangles exist in the corporate world too" (Great Quote) and also enjoined Lilly from disclosing any confidential info about Byetta to any reps who would sell linagliptin. Lilly expressed disapointment in the court order and the mandatory expression of confidence that it would prevail upon further legal action.
The analysts have had a field day in dissecting the company dynamics and motives underlying this squabble. Read the post from the Pharmalot blog above for some of the intrigue. Some analysts think it woudl be better for Lilly to buy out Amylin or for the two to go their separate ways.
Posted by Bruce Lehr May 26th 2011.